ATCC to Present at Upcoming Association of Molecular Pathology Conference
7 Nov 2016
Subject matter experts to emphasize the importance and need for consistent, reliable reference standards to help confront global health threats such as Zika at AMP 2016.
Subject matter experts from ATCC, a global leader in biological materials development, management and standards, will be presenting at the upcoming Association of Molecular Pathology (AMP) conference in Charlotte, North Carolina.
Liz Kerrigan, director of Commercial Partnerships and Standards, is participating in the AMP Reference Material Forum on Nov. 8, and will discuss ATCC's Zika virus reference materials. This forum will discuss reference materials availability and requirements for test validation, quality control, and proficiency testing.
ATCC is supporting Zika vaccine efficacy testing and the development of molecular-based assays, with an expanding collection of reference materials and solutions including:
- In vivo and tissue culture-adapted strains;
- Genomic and synthetic nucleic acid preparations;
- Inactivated materials;
- Host cell lines and reagents; and
- Custom solutions for expansion, titering, and banking.
Dr. Maryellen de Mars, senior director of Standards Resource Center, is speaking at the AMP International Showcase on Nov. 9, on advancing standards for clinical diagnostics. Specifically, she will talk about the need for global reference materials and standardization among all clinical diagnostic laboratories.
"Our contributions to the AMP conference reflect ATCC's leadership and commitment to supporting the scientific community as we partner to address global health issues around the world," said Dr. Raymond H. Cypess, ATCC CEO. "As with other vector-borne disease threats such as Dengue, Chikungunya and West Nile viruses, ATCC is playing an integral role in supporting R&D and quality control in molecular testing related to the Zika virus. Our high-quality, traceable and authenticated materials are used as reference standards for vaccines, treatments, and diagnostic tools developed to confront health threats like Zika."